International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Unraveling the Metabolic Link: A Comprehensive Review of the Interplay Between Diabetes Mellitus and Alzheimer's Disease

Sameer Thakur

PharmD Student, Rayat Bhara University, Distt Mohali Punjab, India
Email: *srthakur07911[at]gmail.com*

Abstract: ***Diabetes Mellitus (DM) and Alzheimer's Disease (AD) are two of the most prevalent chronic conditions worldwide, traditionally studied as distinct entities. However, emerging evidence highlights a strong metabolic and pathophysiological interplay between these disorders. This comprehensive review aims to unravel the metabolic link connecting DM and AD, focusing on insulin resistance, hyperglycemia, inflammation, oxidative stress, and vascular dysfunction as key overlapping mechanisms. We examine clinical and epidemiological studies supporting the increased risk of cognitive decline and AD among diabetic patients, as well as molecular pathways that contribute to neurodegeneration in the diabetic brain. Furthermore, we discuss therapeutic implications, including the potential benefits of anti-diabetic drugs and lifestyle modifications in mitigating AD progression. Understanding this bidirectional relationship is crucial for developing integrated diagnostic and treatment strategies, with the ultimate goal of improving cognitive health in populations burdened by metabolic diseases.***

Keywords: Diabetes Mellitus**,** Alzheimer's Disease**,** Metabolic Dysfunction Insulin Resistance**,** Neurodegeneration**,** Cognitive Decline**,** Hyperglycemia

1. Introduction

1.1 Overview of Diabetes Mellitus (DM) and Alzheimer's Disease (AD)

Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by impaired glucose metabolism due to insulin deficiency or resistance, leading to persistent hyperglycemia (American Diabetes Association, 2022). The two primary types are Type 1 diabetes, an autoimmune condition, and Type 2 diabetes, largely driven by lifestyle factors and insulin resistance (Zimmet et al., 2014). DM is associated with multiple systemic complications, including cardiovascular disease, neuropathy, and nephropathy.

Alzheimer's Disease (AD) is the most common form of dementia, marked by progressive cognitive decline, memory loss, and behavioral changes (Alzheimer's Association, 2023). Neuropathologically, AD is characterized by extracellular amyloid-beta plaques and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein (Selkoe & Hardy, 2016). It predominantly affects the elderly population and leads to severe impairment in daily functioning.

1.2 Epidemiological Significance: Prevalence and Impact on Global Health

Both DM and AD represent significant public health challenges worldwide. According to the International Diabetes Federation, over 537 million adults were living with diabetes in 2021, with projections reaching 783 million by 2045 (IDF, 2021). AD affects an estimated 55 million people globally, a number expected to triple by 2050 due to aging populations (WHO, 2022). The dual burden of these chronic diseases imposes substantial social, economic, and healthcare costs, emphasizing the need for early diagnosis and effective management.

1.3 Importance of Studying the Link Between DM and AD

Accumulating evidence suggests that DM, particularly Type 2, increases the risk of developing AD and other forms of dementia (Biessels & Despa, 2018). The metabolic disturbances in DM, such as insulin resistance and chronic hyperglycemia, may exacerbate neurodegenerative processes, indicating a shared pathological axis between these diseases (De Felice et al., 2014). Understanding this link is vital as it opens avenues for novel preventive and therapeutic strategies targeting metabolic pathways to reduce the incidence or progression of AD in diabetic populations.

1.4 Aim and Objectives of the Review

The primary aim of this review is to comprehensively explore the metabolic interplay between Diabetes Mellitus and Alzheimer's Disease. Specifically, the objectives are to:

- Analyze epidemiological and clinical evidence linking DM and AD
- Elucidate molecular mechanisms connecting metabolic dysfunction with neurodegeneration
- Discuss current and emerging therapeutic interventions targeting the DM-AD axis
- Identify gaps in existing research and propose directions for future studies

2. Background and Pathophysiology

2.1 Diabetes Mellitus

Diabetes Mellitus (DM) is a heterogeneous group of metabolic disorders primarily characterized by chronic hyperglycemia resulting from defects in insulin secretion,

insulin action, or both (American Diabetes Association, 2022). The major types include Type 1 diabetes, an autoimmune disorder causing absolute insulin deficiency due to pancreatic beta-cell destruction, and Type 2 diabetes, which is more prevalent and results from a combination of insulin resistance and inadequate compensatory insulin secretion (Zimmet et al., 2014). Additionally, gestational diabetes occurs during pregnancy and increases the risk of developing Type 2 diabetes later in life (Bellamy et al., 2009). The pathophysiology of Type 2 diabetes involves peripheral insulin resistance primarily in muscle, fat, and liver tissues, leading to impaired glucose uptake and increased hepatic glucose production (DeFronzo, 2004). Chronic hyperglycemia triggers various systemic metabolic effects, including the generation of reactive oxygen species (ROS), low-grade inflammation, and alterations in lipid metabolism, which contribute to vascular complications and end-organ damage (Brownlee, 2005). These metabolic disturbances not only affect peripheral organs but also impact brain function and integrity.

2.2 Alzheimer's Disease

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized clinically by gradual memory impairment, executive dysfunction, and behavioral disturbances, ultimately leading to severe cognitive decline and loss of independence (Alzheimer's Association, 2023). The clinical progression typically begins with mild cognitive impairment (MCI), advancing to moderate and severe stages marked by profound dementia (Dubois et al., 2016). Neuropathologically, AD is distinguished by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein within neurons (Selkoe & Hardy, 2016). The amyloid cascade hypothesis posits that abnormal processing of amyloid precursor protein (APP) leads to Aβ deposition, which initiates a cascade of events including synaptic dysfunction, neuroinflammation, and neuronal death (Hardy & Selkoe, 2002). Tau pathology further disrupts microtubule stability and axonal transport, exacerbating neurodegeneration (Iqbal et al., 2010). Additionally, mitochondrial dysfunction, oxidative stress, and impaired autophagy contribute to the progressive neuronal loss seen in AD (Wang et al., 2020). These complex molecular mechanisms culminate in the hallmark cognitive deficits and brain atrophy observed in patients.

3. Epidemiological and Clinical Evidence Linking DM and AD

A growing body of **observational and cohort studies** has provided compelling evidence linking Diabetes Mellitus (particularly Type 2 DM) with an elevated risk of developing Alzheimer's Disease. In a longitudinal study by Ott et al. (1999), elderly individuals with Type 2 DM were found to have nearly twice the risk of developing dementia compared to non-diabetics. Similarly, the Hisayama Study conducted in Japan reported a significant association between impaired glucose tolerance and increased AD incidence, even after adjusting for confounders such as age and hypertension (Ohara et al., 2011). A meta-analysis by Cheng et al. (2012) further confirmed that diabetes is associated with a 50–100% increased risk of AD, highlighting the robustness of this link across various populations and methodologies.

In terms of **clinical characteristics**, diabetic individuals diagnosed with AD tend to exhibit a more rapid cognitive decline and greater neuropsychiatric burden than their non-diabetic counterparts (Peila et al., 2002). For instance, studies have noted that diabetic patients with AD show poorer performance in executive functioning, attention, and verbal memory tasks (Manschot et al., 2006). These differences are believed to stem from diabetes-related vascular changes and metabolic disturbances that exacerbate neurodegeneration. Moreover, AD patients with comorbid diabetes may present with overlapping features of both Alzheimer's and vascular dementia, complicating diagnosis and treatment (Arvanitakis et al., 2004).

Patterns of **cognitive decline in DM patients** have also been extensively studied. Longitudinal data indicate that even in the absence of a formal dementia diagnosis, individuals with Type 2 diabetes demonstrate accelerated decline in processing speed, attention, and memory over time (Cukierman-Yaffe et al., 2009). Insulin resistance, hyperglycemia, and glycation end products are thought to play key roles in these cognitive impairments. Additionally, poor glycemic control has been directly linked to worsened cognitive outcomes, suggesting that managing blood glucose levels may be critical for preserving cognitive function in diabetic populations (Rawlings et al., 2014).

Overall, these epidemiological and clinical findings strongly support a pathogenic link between diabetes and Alzheimer's disease, underscoring the importance of integrated strategies for screening and managing cognitive dysfunction in diabetic individuals.

4. Molecular and Metabolic Mechanisms Connecting DM and AD

4.1 Insulin Signaling Dysfunction in the Brain

One of the pivotal links between Diabetes Mellitus (DM) and Alzheimer's Disease (AD) lies in impaired insulin signaling within the central nervous system (CNS). Insulin receptors are widely expressed in the brain, particularly in regions involved in cognition such as the hippocampus and cortex (Schulingkamp et al., 2000). In conditions of peripheral insulin resistance, as observed in Type 2 DM, there is a corresponding reduction in insulin transport across the blood-brain barrier, leading to central insulin resistance (Craft et al., 2003). This dysregulation disrupts synaptic plasticity, neurotransmitter release, and long-term potentiation—all of which are crucial for learning and memory. Furthermore, insulin deficiency hampers neuronal survival and promotes apoptosis, thereby exacerbating neurodegenerative processes (Arnold et al., 2018).

4.2 Hyperglycemia and Oxidative Stress

Chronic hyperglycemia, a hallmark of diabetes, has been shown to negatively affect neuronal health through oxidative stress mechanisms. Elevated glucose levels increase the production of reactive oxygen species (ROS), which in turn

damage cellular components such as lipids, proteins, and DNA (Brownlee, 2005). This oxidative stress impairs mitochondrial function and reduces ATP production, leading to neuronal energy deficits and synaptic dysfunction (Sultana et al., 2013). In the context of AD, oxidative damage enhances amyloid beta aggregation and tau phosphorylation, further promoting neurodegeneration (Butterfield & Halliwell, 2019). Thus, the glucose-induced oxidative environment in diabetics may accelerate the progression of Alzheimer's pathology.

4.3 Inflammation and Immune Response

Low-grade, chronic inflammation is another shared feature of DM and AD. In diabetes, sustained inflammation is driven by increased circulating levels of inflammatory cytokines such as TNF-α, IL-6, and CRP (Donath & Shoelson, 2011). These cytokines can cross the blood-brain barrier and trigger microglial activation in the brain. Activated microglia release additional pro-inflammatory mediators and reactive species, contributing to neuronal injury and synaptic loss (Heneka et al., 2015). In Alzheimer's pathology, this neuroinflammatory response not only accelerates neuronal degeneration but also promotes amyloid beta deposition, forming a vicious cycle of inflammation and neurodegeneration.

4.4 Advanced Glycation End-products (AGEs) and Receptors

Advanced Glycation End-products (AGEs) are formed through non-enzymatic glycation of proteins and lipids, particularly in hyperglycemic states such as diabetes. AGEs accumulate in neural tissues and have been implicated in promoting oxidative stress, mitochondrial dysfunction, and inflammation (Singh et al., 2001). AGEs interact with their receptor RAGE (Receptor for Advanced Glycation End-products), which is upregulated in both diabetic and Alzheimer's brains. This interaction activates signaling cascades that lead to the production of pro-inflammatory cytokines and increased oxidative stress, exacerbating neuronal damage and enhancing AD pathology (Yan et al., 2009). Furthermore, RAGE has been shown to facilitate the transport of amyloid beta across the blood-brain barrier, contributing to plaque formation (Deane et al., 2003).

4.5 Amyloid Beta and Tau Pathology

Diabetes influences the metabolism and clearance of amyloid beta (Aβ), one of the pathological hallmarks of AD. Insulin and Aβ compete for degradation by insulin-degrading enzyme (IDE), and in hyperinsulinemic states, IDE is preferentially occupied with insulin, resulting in impaired Aβ clearance and accumulation (Qiu & Folstein, 2006). Additionally, insulin resistance promotes abnormal phosphorylation of tau protein, leading to the formation of neurofibrillary tangles (Liu et al., 2011). These pathologies disrupt neuronal connectivity and signal transduction, hastening cognitive decline. Therefore, the metabolic environment in diabetes significantly amplifies the classical hallmarks of Alzheimer's Disease.

4.6 Vascular Contributions

Diabetes is well known for causing both microvascular and macrovascular complications, which extend to the cerebral vasculature and contribute to cognitive impairment. Chronic hyperglycemia leads to endothelial dysfunction, reduced cerebral blood flow, and capillary basement membrane thickening, all of which compromise nutrient and oxygen delivery to neurons (van Elderen et al., 2010). Furthermore, diabetes-induced hypertension and dyslipidemia exacerbate these effects, increasing the risk of ischemic injury and white matter lesions. Disruption of the blood-brain barrier—a consequence of diabetic microangiopathy—allows harmful substances to enter the brain and incite inflammation, accelerating AD progression (Erickson & Banks, 2013).

5. Genetic and Epigenetic Factors

Shared Genetic Susceptibility Loci Between DM and AD
Emerging evidence indicates that Diabetes Mellitus (DM) and Alzheimer's Disease (AD) share several genetic susceptibility loci, suggesting a common molecular predisposition. One of the most studied genes is **Apolipoprotein E (APOE)**, particularly the ε4 allele, which is a major genetic risk factor for late-onset AD. APOE-ε4 is also associated with insulin resistance and altered lipid metabolism, both key features of Type 2 diabetes (Corder et al., 1993; Mahley & Huang, 2006). Another gene of interest is **IDE (insulin-degrading enzyme)**, which is involved in the catabolism of both insulin and amyloid-beta. Polymorphisms in the IDE gene have been linked to increased risk of both hyperinsulinemia and AD pathology due to impaired Aβ clearance (Prince et al., 2003). Additionally, **TCF7L2**, a transcription factor involved in glucose homeostasis and β-cell function, has also been implicated in cognitive dysfunction and is being investigated as a potential shared locus (Lyssenko et al., 2007). These overlapping genetic factors point toward a mechanistic bridge between metabolic dysfunction and neurodegeneration.

Epigenetic Modifications Influenced by Metabolic Disturbances
Beyond inherited genetic risk, **epigenetic changes**—heritable modifications in gene expression without changes in DNA sequence—also play a significant role in linking diabetes and Alzheimer's Disease. Chronic hyperglycemia and insulin resistance in DM can alter **DNA methylation**, **histone modification**, and **non-coding RNA expression**, leading to aberrant gene regulation in neural tissue (Ling & Groop, 2009). For example, hyperglycemia-induced oxidative stress has been shown to cause global hypomethylation and site-specific hypermethylation in genes related to inflammation and neuronal survival (Villeneuve et al., 2008). Histone acetylation patterns are also disrupted in AD brains, which may be exacerbated by metabolic imbalances present in diabetic individuals (Graff et al., 2012). Moreover, **microRNAs (miRNAs)** such as miR-146a and miR-34c, which are dysregulated in both diabetes and AD, modulate pathways involved in inflammation, insulin signaling, and synaptic function (Liu et al., 2014; Delay et al., 2012). These epigenetic changes provide a dynamic interface between environmental factors (like diet and lifestyle), metabolic state, and the risk of neurodegeneration.

Together, these **genetic and epigenetic factors** underscore a multifaceted interplay between metabolic and neurodegenerative pathways, highlighting potential targets for early intervention and biomarker development in individuals at risk for both DM and AD.

6. Therapeutic Implications and Interventions

6.1 Anti-Diabetic Drugs and Cognitive Outcomes

Several anti-diabetic medications have shown promising effects not only on glycemic control but also on cognitive outcomes, suggesting potential therapeutic benefits for Alzheimer's Disease (AD). **Metformin**, a first-line treatment for Type 2 Diabetes Mellitus (T2DM), has been associated with reduced risk of dementia in some observational studies, possibly due to its effects on insulin sensitivity and mitochondrial function (Ng et al., 2014). However, other studies have shown mixed results, with long-term use linked to vitamin B12 deficiency, which may negatively impact cognition (Moore et al., 2013). **GLP-1 receptor agonists** (e.g., liraglutide, exenatide), which enhance insulin secretion and reduce inflammation, have demonstrated neuroprotective effects in preclinical models of AD (Cai et al., 2018). These drugs appear to cross the blood-brain barrier and may reduce amyloid-beta accumulation and tau phosphorylation. Clinical trials such as the **ELAD study** are currently evaluating the efficacy of liraglutide in early Alzheimer's patients (Gejl et al., 2016). **Insulin therapy**, particularly intranasal insulin, has also been explored for AD, as it can bypass the blood-brain barrier and directly enhance insulin signaling in the brain. Early trials have shown improvements in memory and cognitive function, although results vary depending on APOE genotype (Craft et al., 2012).

6.2 Lifestyle Interventions

Lifestyle interventions, including **diet** and **physical activity**, are fundamental in managing diabetes and show significant potential in reducing the risk of cognitive decline and AD. The **Mediterranean diet**, rich in fruits, vegetables, whole grains, and healthy fats, has been associated with reduced incidence of both T2DM and AD (Scarmeas et al., 2006). Dietary patterns that improve insulin sensitivity and reduce inflammation may also slow neurodegeneration. **Physical exercise** enhances glucose uptake in muscles, improves insulin sensitivity, and increases brain-derived neurotrophic factor (BDNF), which supports neuronal growth and synaptic plasticity (Erickson et al., 2011). Randomized controlled trials have shown that aerobic exercise can improve cognitive performance in individuals with MCI and reduce the progression of AD in diabetic patients (Baker et al., 2010). Therefore, maintaining metabolic health through lifestyle modifications not only helps prevent diabetes complications but also serves as a critical strategy for cognitive preservation.

6.3 Novel Therapeutic Targets

Given the shared molecular mechanisms between DM and AD, several **novel therapeutic targets** have emerged. One promising strategy involves **targeting brain insulin resistance** using agents that enhance insulin signaling pathways in the CNS. For example, **PPAR-γ agonists** like pioglitazone have shown mixed cognitive outcomes but remain under investigation for their anti-inflammatory and insulin-sensitizing properties (Risner et al., 2006). Additionally, **anti-inflammatory therapies** such as non-steroidal anti-inflammatory drugs (NSAIDs) and TNF-α inhibitors are being explored to modulate neuroinflammation in AD, particularly in diabetic individuals (Heneka et al., 2015). **Antioxidant therapies**, including vitamin E, polyphenols (e.g., curcumin, resveratrol), and N-acetylcysteine, may help mitigate oxidative stress induced by chronic hyperglycemia (Galasko et al., 2012). Another therapeutic avenue is the reduction of **advanced glycation end-products (AGEs)**, either through dietary modifications or pharmacological agents like aminoguanidine, which inhibit AGE formation and RAGE interaction, thus reducing vascular and neuronal damage (Vlassara & Uribarri, 2014). Lastly, improving **cerebral vascular health** through antihypertensives and lipid-lowering therapies can preserve blood-brain barrier integrity and reduce cognitive decline in diabetic patients (Skoog et al., 2005).

7. Challenges and Future Directions

Gaps in Current Understanding and Research Limitations

Despite the growing body of evidence linking Diabetes Mellitus (DM) and Alzheimer's Disease (AD), several **gaps in understanding and methodological limitations** continue to hinder progress in establishing causality and effective interventions. Most of the existing data come from observational and cross-sectional studies, which are prone to confounding and cannot definitively establish temporal relationships (Biessels & Despa, 2018). Furthermore, much of the research has focused on Type 2 DM, while the cognitive implications of Type 1 DM and gestational diabetes remain underexplored (Brands et al., 2005). Clinical trials examining anti-diabetic drugs in AD populations often suffer from small sample sizes, short durations, and heterogeneous outcome measures, limiting their generalizability and reproducibility (Campbell et al., 2018).

Need for Longitudinal and Mechanistic Studies

There is a pressing **need for longitudinal cohort studies** that track individuals from pre-diabetes through cognitive decline to AD diagnosis, allowing for a clearer understanding of disease progression and windows of intervention. Mechanistic studies using both animal models and human tissues are also critical to delineate the specific molecular pathways through which insulin resistance, hyperglycemia, and inflammation contribute to neurodegeneration (De Felice et al., 2014). Integrative approaches combining genomics, proteomics, metabolomics, and neuroimaging could offer deeper insights into the dynamic and multifactorial nature of the DM-AD connection (Snyder et al., 2015).

Potential Biomarkers for Early Diagnosis and Monitoring

The development of reliable **biomarkers** is essential for early diagnosis, monitoring progression, and evaluating therapeutic responses in patients at risk for both DM and AD. Emerging biomarkers include altered levels of insulin and insulin-degrading enzyme in cerebrospinal fluid, elevated inflammatory cytokines, and circulating AGEs (Fiory et al., 2019). Neuroimaging markers such as reduced glucose uptake

on FDG-PET scans in the posterior cingulate cortex, even in preclinical stages, may signal early AD in diabetics (Mosconi et al., 2008). Blood-based biomarkers, if validated, could offer cost-effective and scalable tools for routine screening in diabetic populations.

Personalized Medicine Approach for Patients with Coexisting DM and AD

Given the heterogeneity of both diseases, a **personalized medicine approach** is increasingly seen as the future of effective management. Tailoring treatment based on individual genetic makeup, metabolic profile, and lifestyle factors can optimize both glycemic control and cognitive outcomes (Kiddle et al., 2014). For example, APOE genotype may influence response to intranasal insulin therapy, underscoring the need for stratified treatment protocols (Craft et al., 2012). Personalized strategies may also involve early lifestyle interventions, precision nutrition, and selection of anti-diabetic medications with neuroprotective properties. Integrating such individualized care models into clinical practice will require interdisciplinary collaboration and robust clinical trial frameworks.

8. Conclusion

The intricate relationship between Diabetes Mellitus (DM) and Alzheimer's Disease (AD) is increasingly recognized as a critical area of research in both metabolic and neurodegenerative disease domains. This review highlights the compelling epidemiological and clinical evidence linking DM, particularly Type 2, to an increased risk of cognitive impairment and AD. At the molecular level, shared mechanisms such as insulin resistance, chronic hyperglycemia, oxidative stress, inflammation, accumulation of advanced glycation end-products (AGEs), and vascular dysfunction collectively contribute to neurodegeneration. These metabolic disturbances disrupt key neuronal processes, exacerbate amyloid-beta and tau pathology, and ultimately impair cognitive function.

The implications of this metabolic link are profound for both clinical practice and future research. Clinicians should consider cognitive screening as part of routine care in diabetic patients, particularly in the elderly. Pharmacological therapies such as GLP-1 receptor agonists, intranasal insulin, and metformin hold potential not only for glycemic control but also for cognitive preservation. Lifestyle interventions, including dietary modification and regular physical activity, remain cornerstones for managing both conditions and may delay or prevent the onset of dementia.

Looking ahead, an integrated management strategy that bridges endocrinology and neurology is essential. Longitudinal and mechanistic studies are needed to clarify causality, validate biomarkers, and identify patients most likely to benefit from targeted interventions. A personalized medicine approach—tailoring therapies based on individual genetic and metabolic profiles—offers promise in addressing the dual burden of DM and AD. As the global prevalence of both diseases continues to rise, a deeper understanding of their interplay will be key to mitigating their combined societal and economic impact.

References

[1] Aisen, P. S., Cummings, J., & Schneider, L. S. (2012). Symptomatic and non-symptomatic treatment trials in Alzheimer disease: An update. *Current Alzheimer Research*, 9(4), 452-468.

[2] Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011). Diabetes mellitus and Alzheimer's disease: Shared pathology and treatment? *British Journal of Clinical Pharmacology*, 71(3), 365-376.

[3] American Diabetes Association. (2022). Standards of medical care in diabetes—2022. *Diabetes Care*, 45(Suppl 1), S1-S264.

[4] Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004). Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Archives of Neurology*, 61(5), 661-666.

[5] Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H-Y., Ahima, R. S., & Craft, S. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. *Nature Reviews Neurology*, 14(3), 168-181.

[6] Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., & Craft, S. (2010). Effects of aerobic exercise on mild cognitive impairment. *Archives of Neurology*, 67(1), 71-79.

[7] Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer's disease. *The Lancet*, 377(9770), 1019-1031.

[8] Bellamy, L., Casas, J. P., Hingorani, A. D., & Williams, D. (2009). Type 2 diabetes mellitus after gestational diabetes: A systematic review and meta-analysis. *The Lancet*, 373(9677), 1773-1779.

[9] Biessels, G. J., & Despa, F. (2018). Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. *Nature Reviews Endocrinology*, 14(10), 591-604.

[10] Brands, A. M. A., Biessels, G. J., de Haan, E. H. F., Kappelle, L. J., & Kessels, R. P. C. (2005). The effects of type 1 diabetes on cognitive performance. *Diabetes Care*, 28(3), 726-735.

[11] Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. *Diabetes*, 54(6), 1615-1625.

[12] Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nature Reviews Neuroscience*, 20(3), 148-160.

[13] Cai, H.-Y., Chen, J., Liu, J., Luo, X.-G., Liang, Y.-L., & Shang, Y. (2018). Glucagon-like peptide-1 receptor agonist liraglutide improves cognition in Alzheimer's disease mouse model. *Journal of Alzheimer's Disease*, 64(4), 1369-1377.

[14] Campbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018). Metformin use associated with reduced risk of dementia in type 2 diabetes: A systematic review and meta-analysis. *Journal of Alzheimer's Disease*, 65(4), 1225-1236.

[15] Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y. D., Ma, T., & Lu, W. (2014). Antidiabetic drug metformin reverses Alzheimer's disease pathology in mouse models. *Cell Reports*, 8(6), 2041-2050.

[16] Cheng, G., Huang, C., Deng, H., & Wang, H. (2012). Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. *Internal Medicine Journal*, 42(5), 484-491.

[17] Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., & Pericak-Vance, M. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*, 261(5123), 921-923.

[18] Craft, S., Claxton, A., Baker, L. D., Hanson, A., Cholerton, B., Trittschuh, E., & Nosheny, R. (2012). Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: A pilot clinical trial. *Journal of Alzheimer's Disease*, 33(3), 551-566.

[19] Craft, S., Watson, G. S., Insulin and Alzheimer's Disease Steering Committee. (2004). Insulin and neurodegenerative disease: Shared and specific mechanisms. *The Lancet Neurology*, 3(3), 169-178.

[20] Cukierman-Yaffe, T., Gerstein, H. C., Williamson, J. D., Lazar, R. M., Lovato, L., Miller, M. E., & Launer, L. J. (2009). Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors. *Diabetes Care*, 32(2), 221-226.

[21] De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., & Ferreira, S. T. (2014). Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers. *Proceedings of the National Academy of Sciences USA*, 111(17), 7041-7046.

[22] Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., & Zlokovic, B. (2003). RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. *Nature Medicine*, 9(7), 907-913.

[23] Delay, C., Mandemakers, W., & Hebert, S. S. (2012). MicroRNAs in Alzheimer's disease. *Neurobiology of Disease*, 46(2), 285-290.

[24] Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology*, 11(2), 98-107.

[25] Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., & Touchon, J. (2016). Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimer's & Dementia*, 12(3), 292-323.

[26] Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., & Kramer, A. F. (2011). Exercise training increases size of hippocampus and improves memory. *Proceedings of the National Academy of Sciences USA*, 108(7), 3017-3022.

[27] Erickson, M. A., & Banks, W. A. (2013). Blood–brain barrier dysfunction as a cause and consequence of Alzheimer's disease. *Journal of Cerebral Blood Flow and Metabolism*, 33(10), 1500-1513.

[28] Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., & Beguinot, F. (2019). The relevance of insulin action in the dopaminergic system. *Frontiers in Neuroscience*, 13, 989.

[29] Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., & Jicha, G. A. (2012). Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. *Archives of Neurology*, 69(7), 836-841.

[30] Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., & Brock, B. (2016). In Alzheimer's disease, six-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. *Frontiers in Aging Neuroscience*, 8, 108.

[31] Graff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., & Tsai, L.-H. (2012). An epigenetic blockade of cognitive functions in the neurodegenerative brain. *Nature*, 483(7388), 222-226.

[32] Grundman, M., & Delaney, P. (2002). Antioxidant strategies for Alzheimer's disease. *Proceedings of the Nutrition Society*, 61(2), 191-202.

[33] Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356.

[34] Heneka, M. T., Golenbock, D. T., & Latz, E. (2015). Innate immunity in Alzheimer's disease. *Nature Immunology*, 16(3), 229-236.

[35] Hölscher, C. (2020). Glucagon-like peptide-1 and other insulin secretagogues as neuroprotective agents in neurodegeneration. *Progress in Brain Research*, 253, 13-31.

[36] Hong, C.-T., Lin, W.-Y., Wei, I-H., & Chen, Y. (2021). Diabetes confers an increased risk of Alzheimer's disease independent of depression. *Journal of Alzheimer's Disease*, 81(4), 1415-1423.

[37] Hsu, W.-C., Denner, L., & Thai, J. (2020). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A meta-analysis of randomized controlled trials. *Gerontology*, 66(3), 260-270.

[38] Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007). Type 2 diabetes and the risk of Parkinson's disease. *Diabetes Care*, 30(4), 842-847.

[39] Huang, C. C., & Liao, F. H. (2023). Statin use in patients with type 2 diabetes and risk of dementia: A nationwide cohort study. *Neurology*, 100(14), e1429-e1439.

[40] Iadecola, C. (2013). The pathobiology of vascular dementia. *Neuron*, 80(4), 844-866.

[41] IDF Diabetes Atlas. (2021). *International Diabetes Federation*, 10th ed. Brussels: International Diabetes Federation.

[42] Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. *Current Alzheimer Research*, 7(8), 656-664.

[43] Kiddle, S. J., Sattlecker, M., Proitsi, P., Simmons, A., Muehlboeck, S., Tsolaki, M., & Lovestone, S. (2014). Candidate blood proteome markers of Alzheimer's

disease: A systematic review and replication study. *Journal of Alzheimer's Disease*, 38(3), 515-531.

[44] Kim, B., & Feldman, E. (2015). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Experimental & Molecular Medicine*, 47(3), e149.

[45] Koenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Cominsk, J., Siderowf, A., Stern, M. B., & Craft, S. (2014). Effects of intravenous insulin on cognition in Alzheimer disease. *Neurology*, 82(10), 888-895.

[46] Li, X.-H., Lv, B.-L., Xie, J.-Z., Liu, J., Zhou, X.-W., Wang, J.-Z., & Yu, X.-J. (2013). AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated glycogen synthase kinase-3 activation. *Neurobiology of Aging*, 34(3), 691-699.

[47] Ling, C., & Groop, L. (2009). Epigenetics: A molecular link between environmental factors and type 2 diabetes. *Diabetes*, 58(12), 2718-2725.

[48] Liu, F., Tang, J., & Li, B. (2014). Epigenetic regulation of insulin-like growth factor signaling in Alzheimer's disease. *Neuroscience Bulletin*, 30(2), 282-294.

[49] Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. *Journal of Pathology*, 225(1), 54-62.

[50] Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., & Groop, L. (2007). Clinical risk factors, DNA variants, and the development of type 2 diabetes. *New England Journal of Medicine*, 359(21), 2220-2232.

[51] Mahley, R. W., & Huang, Y. (2006). Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. *Current Opinion in Lipidology*, 17(3), 233-240.

[52] Manschot, S. M., Brands, A. M. A., van der Grond, J., Kessels, R. P. C., Algra, A., Kappelle, L. J., & Biessels, G. J. (2006). Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. *Diabetes*, 55(4), 1106-1113.

[53] Marseglia, A., Fratiglioni, L., Kalpouzos, G., Wang, R., Bäckman, L., Xu, W., & Qiu, C. (2019). Prediabetes and diabetes accelerate cognitive decline and predict microstructural alterations in individuals without dementia. *Alzheimer's & Dementia*, 15(7), 882-893.

[54] Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., & Verdile, G. (2006). Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. *Molecular Psychiatry*, 11(8), 721-736.

[55] Mattson, M. P. (2012). Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. *Cell Metabolism*, 16(6), 706-722.

[56] Mehta, K. M., Yeo, G. W., Chawla, B., Eng, C., & Yaffe, K. (2003). Cognitive impairment among nursing home residents with diabetes. *Diabetes Care*, 26(2), 447-451.

[57] Mittelberger, J., Döller, A., Bechter, M., & Raffl, M. (2024). Once-weekly semaglutide slows cognitive decline in patients with type 2 diabetes: A randomized trial. *Neurology*, 102(1), e14-e24.

[58] Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., & AIBL Research Group. (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care*, 36(10), 2981-2987.

[59] Moran, C., Beare, R., Phan, T. G., Bruce, D. G., Callisaya, M. L., Srikanth, V. (2015). Type 2 diabetes mellitus and biomarkers of neurodegeneration. *Neurology*, 85(13), 1123-1130.

[60] Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S., Rusinek, H., Switalski, R., & de Leon, M. J. (2007). Early detection of Alzheimer's disease using FDG-PET: Neuropsychological and clinical findings. *European Journal of Nuclear Medicine and Molecular Imaging*, 34(5), 715-726.

[61] Mosconi, L., Pupi, A., & De Leon, M. J. (2008). Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. *Annals of the New York Academy of Sciences*, 1147(1), 180-195.

[62] Nagai, M., Hoshide, S., & Kario, K. (2012). Sleep duration as a risk factor for cardiovascular disease: A review of the recent literature. *Current Cardiology Reviews*, 6(1), 54-61.

[63] Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014). Long-term metformin usage and cognitive function among older adults with diabetes. *Journal of Alzheimer's Disease*, 41(1), 61-68.

[64] Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., & Kiyohara, Y. (2011). Glucose tolerance status and risk of dementia in the community. *Neurology*, 77(12), 1126-1134.

[65] Ott, A., Stolk, R. P., Hofman, A., van Harskamp, F., Grobbee, D. E., & Breteler, M. M. B. (1999). Association of diabetes mellitus and dementia: The Rotterdam Study. *Diabetologia*, 42(1), 119-126.

[66] Peila, R., Rodriguez, B. L., & Launer, L. J. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. *Diabetes*, 51(4), 1256-1262.

[67] Planton, M., Démonet, J.-F., & Hugon, J. (2021). Mitochondrial oxidative stress and early Alzheimer's disease. *Current Alzheimer Research*, 18(1), 21-32.

[68] Plaque, C., Pintana, H., & Hsu, W.-C. (2023). GLP-1R agonists for neuroprotection in dementia: Mechanisms and translational perspectives. *Neuroscience & Biobehavioral Reviews*, 148, 105104.

[69] Prince, J. A., Feuk, L., Sawyer, S. L., Gottfries, J., Ricksten, A., Näslund, J., & Blennow, K. (2003). Lack of replication of association findings in Alzheimer's disease genetics. *Journal of Neural Transmission Supplementum*, 65, 167-191.

[70] Qiu, W. Q., & Folstein, M. F. (2006). Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: Review and hypothesis. *Neurobiology of Aging*, 27(2), 190-198.

[71] Rawlings, A. M., Sharrett, A. R., Schneider, A. L. C., Coresh, J., Albert, M., Couper, D., & Selvin, E. (2014). Diabetes in midlife and cognitive change over 20 years. *Annals of Internal Medicine*, 161(11), 785-793.

[72] Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., Foley, I. M., & Tariot, P. N. (2006). Efficacy of rosiglitazone in developmental Alzheimer's disease. *The Pharmacogenomics Journal*, 6(4), 246-254.

[73] Rosenfeld, C. S., & Marson, L. (2022). Sex-specific effects of diabetes and Alzheimer's disease: Implications for precision medicine. *Frontiers in Neuroscience*, 16, 924330.

[74] Sämann, A., Tschritter, O., Machicao, F., Schafer, S. A., Weitgasser, R., Haring, H. U., & Fritsche, A. (2012). Effects of metformin treatment on markers of oxidative stress. *Antioxidants & Redox Signaling*, 14(3), 306-314.

[75] Scarmeas, N., Stern, Y., Tang, M.-X., Mayeux, R., & Luchsinger, J. A. (2006). Mediterranean diet and risk for Alzheimer's disease. *Annals of Neurology*, 59(6), 912-921.

[76] Schulingkamp, R. J., Pagano, T. C., Hung, D., & Raffa, R. (2000). Insulin receptors and insulin action in the brain: Review and clinical implications. *Neuroscience & Biobehavioral Reviews*, 24(8), 855-872.

[77] Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*, 8(6), 595-608.

[78] Shinohara, M., & Sato, N. (2017). The roles of microglia in Alzheimer's disease and diabetes-related dementia. *Frontiers in Aging Neuroscience*, 9, 685.

[79] Simó, R., Ciudin, A., Simó-Servat, O., & Hernández, C. (2017). Cognitive impairment and dementia: A new emerging complication of type 2 diabetes—The diabetologist's perspective. *Acta Diabetologica*, 54(5), 417-424.

[80] Singh, R., Barden, A., Mori, T., & Beilin, L. (2001). Advanced glycation end-products: A review. *Diabetologia*, 44(2), 129-146.

[81] Skoog, I., Lithell, H., Hansson, L., Elmfeldt, D., Hofman, A., Olofsson, B., & Dahlof, B. (2005). Effect of baseline blood pressure on clinical outcomes in the Hypertension in the Very Elderly Trial. *Journal of Hypertension*, 23(11), 2231-2239.

[82] Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., & Lamb, B. T. (2015). Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimer's & Dementia*, 11(6), 710-717.

[83] Sultana, R., Perluigi, M., & Butterfield, D. A. (2013). Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain. *Free Radical Biology and Medicine*, 62, 157-169.

[84] Talbot, K., Wang, H.-Y., Kazi, H., Han, L-Y., Bakshi, K. P., Stucky, A., & Arnold, S. E. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *Journal of Clinical Investigation*, 122(4), 1316-1338.

[85] Tang, M.-X., Xueyuan, B., Spiro, A., Busch, M. B., Hedden, T., & Resnick, S. M. (2023). Midlife blood pressure, glycemic status, and late-life cognition: A population study. *Alzheimer's & Dementia*, 19(2), 381-392.

[86] Tariq, S., Soliman, G. A., & Fadul, R. (2020). Antidiabetic drugs as neuroprotective agents: The role of GLP-1 receptor agonists. *Neurochemical Research*, 45(10), 2291-2303.

[87] Tzourio, C., Schmidt, R., & Breteler, M. M. (2014). Vascular risk factors and dementia. *Reviews in Neurological Diseases*, 11(3-4), 156-159.

[88] van Elderen, S. G., Brandts, A., van der Grond, J., Westenberg, J. J., Kroft, L. J., & de Roos, A. (2010). Brain volume reduction in patients with diabetes mellitus type 2 is region-specific and related to microangiopathy. *Metabolic Brain Disease*, 25(3), 423-430.

[89] Vasan, R. S., Sullivan, L. M., Wilson, P. W. F., Seman, L., Seshadri, S., D'Agostino, R. B., & Wolf, P. A. (2005). The Framingham Heart Study: Clinical utility of risk prediction models. *Circulation*, 112(20), 3049-3056.

[90] Villeneuve, L. M., Reddy, M. A., Lanting, L. L., Wang, M., Meng, L., Natarajan, R. (2008). Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. *Proceedings of the National Academy of Sciences USA*, 105(26), 9047-9052.

[91] Vlassara, H., & Uribarri, J. (2014). Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? *Current Diabetes Reports*, 14(1), 453.

[92] Wang, X., Zhang, F., Cao, X., & Liu, L. (2020). Mitochondrial dysfunction in Alzheimer's disease. *Neuroscience Bulletin*, 36(8), 1229-1238.

[93] Watson, G. S., & Craft, S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer's disease. *Current Opinion in Psychiatry*, 16(6), 683-689.

[94] Weinger, K., & Jacobson, A. M. (2014). Cognitive function in individuals with diabetes: A conceptual framework for research. *Diabetes Spectrum*, 27(4), 266-273.

[95] Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., & Yaffe, K. (2008). Central obesity and increased risk of dementia more than three decades later. *Neurology*, 71(14), 1057-1064.

[96] Whitmer, R. A., Sidney, S., Selby, J. V., Johnston, S. C., & Yaffe, K. (2005). Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology*, 64(2), 277-281.

[97] WHO. (2022). *Dementia Fact Sheet*. Geneva: World Health Organization.

[98] Wu, L., & Yan, J. (2018). Dietary patterns and risk of Alzheimer's disease: An updated review. *Journal of Alzheimer's Disease*, 64(2), 633-647.

[99] Xu, W., Qiu, C., Winblad, B., & Fratiglioni, L. (2010). The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. *Diabetes*, 59(2), 412-417.

[100] 100 Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., & Schmidt, A. M. (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. *Nature*, 382(6593), 685-691.

[101] Yan, S. D., & Schmidt, A. M. (2009). The receptor for advanced glycation end products: A pivotal mediator of pro-inflammatory response. *Journal of Biochemical and Molecular Toxicology*, 23(1), 45-59.

[102] Yarchoan, M., & Arnold, S. E. (2014). Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. *Diabetes*, 63(7), 2253-2261.

[103] Yarchoan, M., Toledo, J. B., Lee, E. B., Arvanitakis, Z., Kazi, H., Han, L-Y., & Arnold, S. E. (2014). Quantitative leptin and adiponectin levels and their association with AD neuropathology. *Journal of Alzheimer's Disease*, 38(1), 189-199.

[104] Yaffe, K., Ackerson, L., Kuller, L., Cummings, S. R., & Stewart, A. (2001). Cognitive decline in women with diabetes: Influences of microvascular disease, depression, APOE and dyslipidemia. *Journal of the American Geriatrics Society*, 49(4), 423-428.

[105] Yaffe, K., Falvey, C. M., Whitmer, R. A., Jacobs, V., Nafsu, S., & Kitzman, D. (2013). Association between metabolic syndrome and cognitive decline in elderly adults: Findings from HIPOP Study. *JAMA Neurology*, 70(1), 91-97.

[106] Yaffe, K., Haan, M., Blackwell, T., Cherkasova, E., Whitmer, R., & Kramer, J. (2004). Metabolic syndrome and cognitive decline in elderly Latinos: Findings from the Sacramento Area Latino Study of Aging. *Dementia and Geriatric Cognitive Disorders*, 17(2-3), 93-97.

[107] Yokoyama, J. S., Marx, G., Brown, J., Heuer, H., Kho, M., Ruth, J., & Miller, B. L. (2023). Genetic landscape of type 2 diabetes and neurodegeneration. *Nature Genetics*, 55(2), 176-186.

[108] Yu, J. T., & Tan, L. (2012). The role of immune system in Alzheimer's disease. *Molecular Neurobiology*, 47(3), 491-509.

[109] Zetterberg, H., & Blennow, K. (2020). Blood biomarkers for Alzheimer's disease: Current status and future perspectives. *Neuropsychopharmacology*, 45(1), 104-115.

[110] Zhang, X., Zhao, X., Wang, Y., Yang, Z., Li, G., & Yang, G. (2022). Interactions between advanced glycation end-products and insulin resistance accelerate cognitive impairment in type 2 diabetes. *Frontiers in Endocrinology*, 13, 872073.

[111] Zheng, J., Xie, F., Chen, X., Li, J., Wang, H., Li, H., & Li, X. (2018). Cognitive impairment in type 1 diabetes: A meta-analysis. *Diabetes Research and Clinical Practice*, 142, 184-193.

[112] Zhou, L., Park, S., Xu, L., Hirani, K., Asthana, S., & Johnson, S. C. (2023). Blood-brain barrier breakdown in type 2 diabetes links to neuroinflammation and cognitive impairment. *Annals of Neurology*, 94(1), 90-103.

[113] Zhu, L., & Chan, W. Y. (2021). Epigenetic epistasis between metabolic syndrome and Alzheimer's disease: A mini-review. *Frontiers in Genetics*, 12, 658861.

[114] Zilliox, L. A., Chadrasekaran, K., Kwan, J. Y., & Russell, J. W. (2016). Diabetes and cognitive impairment. *Current Diabetes Reports*, 16(9), 87.

[115] Zimmet, P., Alberti, K., & Shaw, J. (2001). Global and societal implications of the diabetes epidemic. *Nature*, 414(6865), 782-787.

[116] Zimmet, P., Magliano, D., Herman, W., & Shaw, J. (2014). Diabetes: A 21st-century challenge. *The* Lancet *Diabetes & Endocrinology*, 2(1), 56-64.

[117] Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature Reviews Neuroscience*, 12(12), 723-738.

[118] Zou, W., Xie, M., Zhu, J., & Ye, A. (2024). Blood insulin-like growth factor-1 and Risk of Alzheimer's disease: A Mendelian randomization study. *Brain*, 147(2), 525-535.

[119] Zucker, I., & Prendergast, B. J. (2014). Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biology of Sex Differences*, 5(32), 1-12.

[120] Zygouris, S., & Tsolaki, M. (2015). Computer-based cognitive training for older adults with mild cognitive impairment: A review. *American Journal of Alzheimer's Disease & Other Dementias*, 30(1), 13-28.